PharmaMar Inició la Fase I Con PM534 en 2022 Con 30 Pacientes ... Estaba Previsto de Tenerlo Completado en Marzo 2025 ... Acaba de Actualizar Dicho Ensayo ... Y Sigue Reclutando Pacientes ... Y Concluira en Octubre 2026 ... 19 Meses Más Tarde de lo Previsto .

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors .

PharmaMar . Precio Objetivo a Cinco Días de IBEXIA : 79,12€ .

TARLATAMAB EN EL MUNDO REAL TAMBIEN SUPERA AL RESTO DE TRATAMIENTOS DE SEGUNDA LÍNEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE ... POR LO QUE POR FIN TENEMOS UNA NUEVA OPCIÓN TERAPÉUTICA EN PARA EL TRATAMIENTO DEL CÁNCER DE PULMÓN MICROCÍTICO EN DONDE HASTA AHORA LOS RESULTADOS QUE SE OBTENÍAN ERAN EXTREMADAMENTE DESFAVORABLES .

EL ESTUDIO LO AVALAN Y FIRMAN ... ONCOLOGOS DE ESTADOS UNIDOS , REINO UNIDO Y ALEMANIA :

Jessie Wang, Gautam Sajeev, Xinglei Chai, Rumbidzai Takundwa, Franziska Dirnberger, Xerxes Pundole, Malaika Pastel, Hongbo Yang, Umit Tapan .

TARLATAMAB, a Bispecific T-cell engager immunotherapy, showed durable response with promising survival outcomes in Patients with previously treated SMALL CELL LUNG CANCER  ( SCLC ) in the phase 2 DeLLphi-301 study. Given the lack of a comparator in DeLLphi-301, this analysis aimed to evaluate the relative efficacy of TARLATAMAB against physicians' choice of therapies in real-world practice .

Patients And Methods : This analysis compared the outcomes of patients in DeLLphi-301 who received TARLATAMAB 10 mg (n = 97) with patients in real-world cancer clinics captured in the Flatiron Health database who received third or later-line comparator therapies for SCLC (n = 184) . Propensity score weighting was used to adjust for differences in key prognostic factors between cohorts  .

Overall survival ( OS ), progression-free survival ( PFS ), time to treatment discontinuation (TTD), time to next treatment or death (TTNTD), and objective response rate (ORR) were compared after weighting .

Results : TARLATAMAB was associated with significantly longer OS, PFS, TTD, and TTNTD, and higher ORR versus comparator therapies . After weighting, the hazard ratios (95% confidence interval [CI]) of tarlatamab versus comparator therapies were 0.45 (0.30, 0.68) for OS, 0.61 (0.43, 0.90) for PFS, 0.57 (0.39, 0.84) for TTD, and 0.45 (0.30, 0.66) for TTNTD . The odds ratio for ORR was 2.80 (95% CI: 1.44, 5.83) . 

CONCLUSIÓN :

THE STUDY FINDINGS SUGGEST THAT TARLATAMAB OFFERS POTENTIAL CLINICAL BENEFITS RELATIVE TO COMPARATOR TREATMENTS .

THIS ANALYSIS UNDERSCORES THE POTENTIAL OF TARLATAMAB TO BECOME A NEW THERAPEUTIC OPTION FOR PREVIOUSLY TREATED SCLC, A DISEASE THAT HAS HISTÓRICALLIY BEEN ASSOCIATED WITH EXTREMELY POOR OUTCOMES AND LÍMITED TREATMENT OPTIONS .